Portfolio Press Release
Diatos Named Among the 2005 Red Herring 100 Europe; Biotech Recognized as One of Most Promising Private European & Israeli Startups
Paris, France - April 14, 2005 — PRNewswire — Diatos S.A. has been recognized as one of a select 100 companies driving the future of technology in Europe and Israel by Red Herring, a US-based media company that covers innovation, technology, financing and entrepreneurial activity. This honor included a presentation by Diatos President & CEO Dr. John Tchelingerian at the Venture Market Europe 2005 conference held in London, April 12-14. Diatos, headquartered in Paris, was founded in 1999 as a spin-off from Institut Pasteur (Paris, France) and is developing new therapies for cancer.
"Diatos is very proud to have been selected among the 100 leading private companies in innovation and technology by Red Herring — an influential authority known throughout the world for its comprehensive analysis of the high tech field. This honor signifies being recognized 'best among the best,'" said Dr. Tchelingerian. "Diatos is using proprietary technologies to develop novel cancer therapeutics and rapidly move them into clinical trials. Being named a Red Herring Europe 100 Winner will broaden our visibility in the international marketplace."
Red Herring's lists of top private companies are an important part of the magazine's tradition of identifying new and innovative technology companies and entrepreneurs. Companies like Google and eBay were spotted in their early days by Red Herring editors as those that would change the way we live and work. This is the first time that Red Herring magazine has compiled a list focused exclusively on the most promising startups in Europe.
About Diatos
Diatos is using its proprietary Diatos Peptide Vector (DPV/Vectocell(R)) intra-cellular/intra-nuclear delivery technology and its proprietary Tumor-Selective Prodrug (TSP) cancer-targeting technology to develop new therapies for cancer and other serious diseases. The company's lead therapeutic candidates, DTS-201 — a doxorubicin prodrug based on the TSP technology concept — and DTS-301 — a novel paclitaxel formulation — are respectively entering Phase I and Phase II clinical trials in 2005.
Diatos has raised 33 million Euros to date from Sofinnova Partners (France), GIMV (Belgium), InterWest Partners (USA), Credit Agricole Private Equity (France), AGF Private Equity (France), NIF Ventures (Japan), Societe Generale Asset Management (France), Sopartec (Belgium), Innoven Partenaires (France) and BFF (Belgium). Diatos is headquartered in Paris and has operations in Belgium and the USA, with a total of 44 employees. For more information, please visit Diatos' website at www.diatos.com.
About Red Herring
Red Herring, Inc., founded in 1993, is a media company whose mission is to cover innovation, technology, financing and entrepreneurial activity. Its staff of award-winning journalists tell readers what's first, what matters and most importantly, why.
Red Herring is dedicated to thorough research, relevant metrics, deep financial analysis, in-depth reporting, crisp writing and thoughtful debate. We are a skeptical, intelligent and trustworthy source of information in technology business. Our primary obligation is to provide the most relevant, honest and independent information and analysis to our audience, with the conviction that an exceptional editorial product is the best catalyst for success and the best way to serve our advertisers and investors. Our content is original, compelling and actionable for industry executives and entrepreneurs.